APA

Fradet V., Toren P., Nguile-Makao M., Lodde M., Lévesque J., Léger C., Caron A., Bergeron A., Ben-Zvi T., Lacombe L., Pouliot F., Tiguert R., Dujardin T. & Fradet Y. (20180313). Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors. : BJU international.

Chicago

Fradet Vincent, Toren Paul, Nguile-Makao Molière, Lodde Michele, Lévesque Jérome, Léger Caroline, Caron André, Bergeron Alain, Ben-Zvi Tal, Lacombe Louis, Pouliot Frédéric, Tiguert Rabi, Dujardin Thierry and Fradet Yves. 20180313. Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors. : BJU international.

Harvard

Fradet V., Toren P., Nguile-Makao M., Lodde M., Lévesque J., Léger C., Caron A., Bergeron A., Ben-Zvi T., Lacombe L., Pouliot F., Tiguert R., Dujardin T. and Fradet Y. (20180313). Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors. : BJU international.

MLA

Fradet Vincent, Toren Paul, Nguile-Makao Molière, Lodde Michele, Lévesque Jérome, Léger Caroline, Caron André, Bergeron Alain, Ben-Zvi Tal, Lacombe Louis, Pouliot Frédéric, Tiguert Rabi, Dujardin Thierry and Fradet Yves. Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors. : BJU international. 20180313.